Our research projects

Professor Timothy Tree and researchers across the UK will set up a network of specialist labs to examine samples from all UK-based trials of immunotherapies for type 1 diabetes. They will carry out state-of-the-art studies of their safety and effectiveness to understand exactly how treatments work to control the immune system, and who could benefit most from different treatments. In the future, immunotherapies could give us a way to prevent, halt and cure type 1 diabetes.

The pancreas-liver-gut axis are a group of organs that work together to control blood sugar levels. Changes in blood flow in these organs have been found in type 2 diabetes. Professor Murphy plans to understand these blood flow changes better and see if they hold the answer to improving current type 2 diabetes treatments or finding new ones. 

The bacteria living in our gut play an important role in our health, and could have a hand in the development of type 2 diabetes. Professor Dumas will study the gut bacteria of people who are at high risk of type 2 diabetes to discover which species of bacteria could be involved in either increasing or reducing the risk of type 2 diabetes. This could help scientists to develop new treatments that change the makeup of our gut bacteria and help to prevent type 2 diabetes.

Polypharmacy is when people are prescribed multiple medications at the same time. It’s common in people with diabetes, and while it can be helpful in many ways, it can also throw up challenges. Professor David McAllister wants to shed more light on polypharmacy in people with diabetes. He’ll study health records and interview people with diabetes and healthcare professionals to understand their experiences. This clearer picture could help to develop approaches to reduce polypharmacy and its harm. 

In many types of diabetes, insulin-producing beta cells in the pancreas become stressed and damaged. Professor Terence Herbert has found that a group of molecules called RNA binding proteins (RBPs) may play an important role in helping beta cells survive this stress. In this project, his PhD student will explore how these proteins work and whether they could help protect beta cells and to prevent or slow the progress of diabetes.

It’s possible to identify people who are very likely to develop type 1 diabetes by looking for markers in the blood that show the immune system has begun attacking the pancreas. Professor Parth Narendran is exploring how a screening programme to test children for these early warning signs could best work in the UK.

The ELSA study will screen 20,000 children using a simple blood test. Screening could ensure children at high risk have the earliest, safest diagnosis possible and give families valuable time to prepare for life with type 1. It could also give children access to promising new treatments designed to delay the full development of type 1 diabetes. ELSA will provide vital insights on how to deliver screening at scale, paving the way for a routine, nationwide type 1 diabetes screening programme in the UK.

People from Black African and Caribbean and South Asian backgrounds are at a higher risk of developing type 2 diabetes and some of its complications than White people. Professor Daniel Cuthbertson will look at differences in body fat stores and insulin response among people from these ethnic groups to uncover biological factors that can contribute to the development of type 2. This could lead to tailored support and treatments to prevent and manage type 2 diabetes based on your ethnicity.

Gestational diabetes can increase the risk of mothers developing type 2 diabetes and heart problems later in life. It could also damage the placenta, which can pose a threat to babies in the womb. These problems might be due to a decrease in specialist immune cells during gestational diabetes. Dr Cristiano Scotta is developing a better way to study the placenta in the lab. His approach could potentially help to develop new treatments that better protect mothers and their babies during and after pregnancy.

Having gestational diabetes can increase the risk of getting type 2 diabetes in later life for both mother and baby. Dr Bowe wants to better understand why. He will study changes in the pancreas that happen during pregnancy in women with gestational diabetes to find out if, and how, this has a lasting impact which puts mum and baby at a greater risk of type 2. This could inform new treatments to help women and their children reduce their risk and make sure fewer people get type 2 diabetes in the future.

Muscle damage is a common but under-studied complication of type 2 diabetes. It reduces mobility and can affect independence. Professor Lee Roberts will explore if a drug licensed to treat problems with how the body processes iron could help to improve muscle health and quality of life. This could improve our understanding of muscle damage in people with type 2 diabetes and provide us with better ways to treat it.